CARDIOVASCULAR JOURNAL OF AFRICA • Volume 33, No 2, March/April 2022 AFRICA 51 CALSAR 5/80 mg, 5/160 mg, 10/160 mg. Each tablet contains amlodipine/valsartan 5/80 mg, 5/160 mg, 10/160 mg respectively. S3 A51/7.1.3/1106, 1107, 1108. For full prescribing information, refer to the professional information approved by SAHPRA, March 2021. 1) Karpov Y, et. al. Amlodipine/valsartan single-pill combination: a prospective, observational evaluation of the real-life safety and effectiveness in the routine treatment of hypertension. Advanced Therapeutics 2012;29(2):134-147. 2) Fogari R, et. al. Effect of valsartan addition to amlodipine on ankle oedema and subcutaneous tissue pressure in hypertensive patients. Journal of Human Hypertension 2007;21:220-224. 3) Data on file. *FDC - Fixed-dose combination. CRA721/10/2021. For further product information contact PHARMA DYNAMICS P O Box 30958 Tokai Cape Town 7966 Fax +27 21 701 5898 Email info@pharmadynamics.co.za CUSTOMER CARE LINE 0860 PHARMA (742 762) / +27 21 707 7000 www.pharmadynamics.co.za AMLODIPINE / VALSARTAN *FDC : • E ectively lowers BP1 • Gets up to 8/10 patients to goal 1 • Works synergistically to reduce oedema2 CALSAR: • Is up to 50% LESS vs the Originator 3 • O ers a UNIQUE 5/80 mg dosage DILIGENT WORKERS NEW INTRODUCING OUR AMLODIPINE / VALSARTAN *FDC RANGE PACKED IN 30 TABLETS | | |
RkJQdWJsaXNoZXIy NDIzNzc=